Targeting annexin A2 reduces tumorigenesis and therapeutic resistance of nasopharyngeal carcinoma

Oncotarget

Volumn 6, Issue 29, 2015, Pages 26946-26959

  Chen, Chang Yu ^a   Lin, Yung Song ^b,c   Chen, Chi Long ^b,d   Chao, Pin Zhir ^e   Chiou, Jeng Fong ^b,d   Kuo, Chia Chun ^d   Lee, Fei Peng ^f   Lin, Yung Feng ^a   Sung, Yu Hsuan ^a   Lin, Yun Tien ^a   Li, Chang Fan ^a   Chen, Yin Ju ^a,d   Chen, Chien Ho ^a  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Annexin A2 (ANXA2); Chemotherapy; Epithelial mesenchymal transition (EMT); Nasopharyngeal carcinoma (NPC); Radiotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; LIPOCORTIN 2; NERVE CELL ADHESION MOLECULE; SHORT HAIRPIN RNA; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; VINCRISTINE; ANTINEOPLASTIC AGENT; ANXA2 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXA2 GENE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RADIOSENSITIVITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; UPREGULATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL TRANSFORMATION; CHEMISTRY; DRUG RESISTANCE; GENETICS; METABOLISM; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PHENOTYPE; PROGNOSIS; SIGNAL TRANSDUCTION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANNEXIN A2; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PHENOTYPE; PROGNOSIS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84944459557     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4521     Document Type: Article

References (53)

1. Sun X, Tong LP, Wang YT, Wu YX, Sheng HS, Lu LJ, Wang W. Can Global Variation of Nasopharynx Cancer Be Retrieved from the Combined Analyses of IARC Cancer Information (CIN) Databases? PloS one. 2011; 6:e22039.
2. Cho WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol cancer. 2007; 6:1.
3. Niedobitek G, Agathanggelou A, Nicholls JM. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: Viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol. 1996; 7:165-174.
4. Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C, Armand JP. Nasopharyngeal carcinomas: an update. Eur J Cancer. 2003; 39:2121-2135.
5. Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma. Cancer. 2005; 103:22-31.
6. Smith C, Tsang J, Beagley L, Chua D, Lee V, Li V, Moss DJ, Coman W, Chan KH, Nicholls J, Kwong D, Khanna R. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res. 2012; 72:1116-1125.
7. Li J, Chen QY, Mo H, Zhang YL, Huang ZF, Zeng YX. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy. Int J Biol Sci. 2011; 7:607-617.
8. Smith C, Khanna R. A new approach for cellular immunotherapy of nasopharyngeal carcinoma. Oncoimmunology. 2012; 1:1440-1442.
9. Giannini A, Bianchi S, Messerini L, Gallo O, Gallina E, Asprella Libonati G, Olmi P, Zampi G. Prognostic significance of accessory cells and lymphocytes in nasopharyngeal carcinoma. Pathol Res Pract. 1991; 187:496-502.
10. Zong YS, Zhang CQ, Zhang F, Ruan JB, Chen MY, Feng KT, Yu ZF. Infiltrating lymphocytes and accessory cells in nasopharyngeal carcinoma. Jpn J Cancer Res. 1993; 84:900-905.
11. Hartmann E, Wollenberg B, Rothenfusser S, Wagner M, Wellisch D, Mack B, Giese T, Gires O, Endres S, Hartmann G. Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer. Cancer Res. 2003; 63:6478-6487.
12. Chao PZ, Hsieh MS, Cheng CW, Hsu TJ, Lin YT, Lai CH, Liao CC, Chen WY, Leung TK, Lee FP, Lin YF, Chen CH. Dendritic cells respond to nasopharygeal carcinoma cells through annexin A2-recognizing DC-SIGN. Oncotarget. 2015; 6:159-170.
13. Bharadwaj A, Bydoun M, Holloway R, Waisman D. Annexin A2 heterotetramer: structure and function. Int J Mol Sci. 2013; 14:6259-6305.
14. Lokman NA, Elder ASF, Ween MP, Pyragius CE, Hoffmann P, Oehler MK, Ricciardelli C. Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. Oncotarget. 2013; 4:1199-1211.
15. Zhang HJ, Yao DF, Yao M, Huang H, Wang L, Yan MJ, Yan XD, Gu X, Wu W, Lu SL. Annexin A2 silencing inhibits invasion, migration, and tumorigenic potential of hepatoma cells. World J Gastroenterol. 2013; 19:3792-3801.
16. Zhai H, Acharya S, Gravanis I, Mehmood S, Seidman RJ, Shroyer KR, Hajjar KA, Tsirka SE. Annexin A2 promotes glioma cell invasion and tumor progression. J Neurosci. 2011; 31:14346-14360.
17. Zheng L, Foley K, Huang L, Leubner A, Mo G, Olino K, Edil BH, Mizuma M, Sharma R, Le DT, Anders RA, Illei PB, Van Eyk JE, Maitra A, Laheru D, Jaffee EM. Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer. PloS one. 2011; 6:e19390.
18. Sharma MR, Koltowski L, Ownbey RT, Tuszynski GP, Sharma MC. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp Mol Pathol. 2006; 81:146-156.
19. Chan CM, Wong SC, Lam MY, Hui EP, Chan JK, Lo ES, Cheuk W, Wong MC, Tsao SW, Chan AT. Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma. Arch Pathol Lab Med. 2008; 132:675-683.
20. Alonso-Alconada L, Santacana M, Garcia-Sanz P, Muinelo-Romay L, Colas E, Mirantes C, Monge M, Cueva J, Oliva E, Soslow RA, Lopez MA, Palacios J, Prat J, Valls J, Krakstad C, Salvesen H, et al. Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer. Int J Cancer. 2015; 136:1863-1873.
21. Tristante E, Martinez CM, Jimenez S, Mora L, Carballo F, Martinez-Lacaci I, de Torre-Minguela C. Association of a characteristic membrane pattern of annexin A2 with high invasiveness and nodal status in colon adenocarcinoma. Transl Res. 2015; 166:196-206.
22. Yang SF, Hsu HL, Chao TK, Hsiao CJ, Lin YF, Cheng CW. Annexin A2 in renal cell carcinoma: expression, function, and prognostic significance. Urol Oncol. 2015; 33:22. e11-21.
23. Liu X, Ma D, Jing X, Wang B, Yang W, Qiu W. Overexpression of ANXA2 predicts adverse outcomes of patients with malignant tumors: a systematic review and meta-analysis. Med Oncol. 2015; 32:392.
24. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006; 7:131-142.
25. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelialmesenchymal transitions in development and disease. Cell. 2009; 139:871-890.
26. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15:178-196.
27. Folberg R, Hendrix MJ, Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J Pathol. 2000; 156:361-381.
28. Wang C, Xiao Q, Li YW, Zhao C, Jia N, Li RL, Cao SS, Cui J, Wang L, Wu Y, Wen AD. Regulatory mechanisms of annexin-induced chemotherapy resistance in cisplatin resistant lung adenocarcinoma. Asian Pac J Cancer Prev. 2014; 15:3191-3194.
29. Lorusso A, Covino C, Priori G, Bachi A, Meldolesi J, Chieregatti E. Annexin2 coating the surface of enlargeosomes is needed for their regulated exocytosis. Embo J. 2006; 25:5443-5456.
30. Cocucci E, Racchetti G, Podini P, Meldolesi J. Enlargeosome traffic: exocytosis triggered by various signals is followed by endocytosis, membrane shedding or both. Traffic. 2007; 8:742-757.
31. Prada I, Cocucci E, Racchetti G, Meldolesi J. The Ca2+-dependent exocytosis of enlargeosomes is greatly reinforced by genistein via a non-tyrosine kinase-dependent mechanism. FEBS letters. 2007; 581:4932-4936.
32. Madureira PA, Hill R, Lee PW, Waisman DM. Genotoxic agents promote the nuclear accumulation of annexin A2: role of annexin A2 in mitigating DNA damage. PloS one. 2012; 7:e50591.
33. Chow BH, Chua DT, Sham JS, Zhang MY, Chow LW, Bi J, Ma NF, Xie D, Loo WT, Fung JM, Fu L, Guan XY. Increased expression of annexin I is associated with drugresistance in nasopharyngeal carcinoma and other solid tumors. Proteomics Clin Appl. 2009; 3:654-662.
34. Zeng GQ, Cheng AL, Tang J, Li GQ, Li MX, Qu JQ, Cao C, Liao L, Xiao ZQ. Annexin A1: a new biomarker for predicting nasopharyngeal carcinoma response to radiotherapy. Med hypotheses. 2013; 81:68-70.
35. Luo W, Yan G, Li L, Wang Z, Liu H, Zhou S, Liu S, Tang M, Yi W, Dong Z, Cao Y. Epstein-Barr virus latent membrane protein 1 mediates serine 25 phosphorylation and nuclear entry of annexin A2 via PI-PLC-PKCalpha/ PKCbeta pathway. Mol Carcinog. 2008; 47:934-946.
36. Castellino RC, Durden DL. Mechanisms of disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol. 2007; 3:682-693.
37. Cheng JC, Chou CH, Kuo ML, Hsieh CY. Radiationenhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene. 2006; 25:7009-7018.
38. Kanagasabai R, Karthikeyan K, Vedam K, Qien W, Zhu Q, Ilangovan G. Hsp27 protects adenocarcinoma cells from UV-induced apoptosis by Akt and p21-dependent pathways of survival. Mol Cancer Res. 2010; 8:1399-1412.
39. Sakamoto K, Holman GD. Emerging role for AS160/ TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab. 2008; 295:E29-37.
40. Rajendran L, Knolker HJ, Simons K. Subcellular targeting strategies for drug design and delivery. Nat Rev Drug Discov. 2010; 9:29-42.
41. Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene. 2005; 24:7443-7454.
42. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8:755-768.
43. Colak S, Medema JP. Cancer stem cells-important players in tumor therapy resistance. FEBS J. 2014; 281:4779-4791.
44. Cojoc M, Mabert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol. 2015; 31:16-27.
45. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, Holland EC. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell. 2009; 4:226-235.
46. Li H, Gao Q, Guo L, Lu SH. The PTEN/PI3K/Akt pathway regulates stem-like cells in primary esophageal carcinoma cells. Cancer Biol Ther. 2011; 11:950-958.
47. Singh S, Trevino J, Bora-Singhal N, Coppola D, Haura E, Altiok S, Chellappan SP. EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like sidepopulation cells in non-small cell lung cancer. Mol Cancer. 2012; 11:73.
48. Chatterjee A, Chatterjee U, Ghosh MK. Activation of protein kinase CK2 attenuates FOXO3a functioning in a PML-dependent manner: implications in human prostate cancer. Cell Death Dis. 2013; 4:e543.
49. Mimeault M, Batra SK. Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med. 2014; 39:3-32.
50. Qin J, Ji J, Deng R, Tang J, Yang F, Feng GK, Chen WD, Wu XQ, Qian XJ, Ding K, Zhu XF. DC120, a novel AKT inhibitor, preferentially suppresses nasopharyngeal carcinoma cancer stem-like cells by downregulating Sox2. Oncotarget. 2015; 6:6944-6958.
51. Zhao QW, Zhou YW, Li WX, Kang B, Zhang XQ, Yang Y, Cheng J, Yin SY, Tong Y, He JQ, Yao HP, Zheng M, Wang YJ. Aktmediated phosphorylation of Oct4 is associated with the proliferation of stemlike cancer cells. Oncol Rep. 2015; 33:1621-1629.
52. Chao PZ, Hsieh MS, Cheng CW, Hsu TJ, Lin YT, Lai CH, Liao CC, Chen WY, Leung TK, Lee FP, Lin YF, Chen CH. Dendritic cells respond to nasopharygeal carcinoma cells through annexin A2-recognizing DC-SIGN. Oncotarget. 2015; 6:159-170.
53. Liao SK, Perng YP, Shen YC, Chung PJ, Chang YS, Wang CH. Chromosomal abnormalities of a new nasopharyngeal carcinoma cell line (NPC-BM1) derived from a bone marrow metastatic lesion. Cancer Genet Cytogenet. 1998; 103:52-58.